ArticleCancer medicine2020
Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression.
Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Brucea javanica oil emulsion as an adjunct to chemoradiotherapy in cervical cancer: a systematic review and meta-analysis of adverse effects reduction and immune enhancement.Oncology reviews · 2026Pooled it
- Prognostic Nutritional Index Predicts Response and Prognosis in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.Frontiers in nutrition · 2022Pooled it
- A Novel Nomogram Combined the Aggregate Index of Systemic Inflammation and PIRADS Score to Predict the Risk of Clinically Significant Prostate Cancer.BioMed research international · 2023Trial
- CT-based variables of perirenal fat are risk factors for assessing pathological T-stage in patients with clear cell renal cell carcinoma.Annals of medicine · 2026Article
- Distribution and function of human long-lasting T cells in aging and non-small cell lung cancer.Frontiers in immunology · 2026Review
- Peripheral blood cells predict the efficacy and prognosis of neoadjuvant immunotherapy combined with chemotherapy for esophageal squamous cell carcinoma.BMC cancer · 2025Article
- Development and Validation of a Brief Self-Report Scale to Measure Perceived Immune Vulnerability (PIV) in Cancer Population.Cancers · 2025Article
- The predictive value of circulating lymphocyte subpopulation characteristics for the prognosis of patients with stage III-IV non-small cell lung cancer treated with EGFR-TKI.Biomedical engineering online · 2025Article
- Spectral Flow Cytometry: The Current State and Future of the Technology.International journal of molecular sciences · 2025Review
- Causal association between immune cell phenotypes and colorectal cancer: a two-sample bidirectional Mendelian randomization analysis.Discover oncology · 2025Article
- Prognostic evaluation in gallbladder carcinoma: Introducing a composite risk model integrating nutritional and immune markers.Biomolecules & biomedicine · 2025Article
- The application of peripheral blood immune profiling in personalized treatment of locally advanced and advanced lung cancer: a nomogram approach.Frontiers in oncology · 2025Article
- Influence of cryoablation versus operation on circulating lymphocyte subsets in patients with early-stage renal cell carcinoma.BMC cancer · 2024Article
- Heterogeneity of lymphocyte subsets in predicting immune checkpoint inhibitor treatment response in advanced lung cancer: an analysis across different pathological types, therapeutic drugs, and age groups.Translational lung cancer research · 2024Article
- Changes in subset distribution and impaired function of circulating natural killer cells in patients with colorectal cancer.Scientific reports · 2024Article
- Immunoinflammatory markers SIRI and NAR as predictors of respiratory distress syndrome and secondary infections in premature infants.Frontiers in cellular and infection microbiology · 2024Article
- Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without PD-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical study.Frontiers in immunology · 2024Article
- Proteomics: Unraveling the Cross Talk Between Innate Immunity and Disease Pathophysiology, Diagnostics, and Treatment Options.Advances in experimental medicine and biology · 2024Review
- Prognostic value of inflammatory nutritional scores in locally advanced esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoimmunotherapy: a multicenter study in China.Frontiers in oncology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to predict the value of lymphocyte subsets in cancer progression. Peripheral blood was obtained from 327 untreated patients with cancer and 158 healthy volunteers. Levels of lymphocyte subsets were determined by flow cytometry. There were decreased levels of natural killer (NK) cells, CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.